News provided byHalozyme Therapeutics, Inc. May 28, 2025, 08:30 ET Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC)…

In this deeply personal episode, Drs. Samantha and Samuel Siegel share their journey of navigating cancer, medical school, and family…

Last night, leading melanoma researchers and clinicians from across the New York , New Jersey, and Connecticut region gathered at…

May is Melanoma Awareness Month—a time to come together, raise awareness, and take meaningful steps toward ending one of the…

Dear Friend, May is Melanoma Awareness Month, a time to honor the progress made in the fight against this deadly…

Mark your calendar—May 2nd is a day to shop for a cause! We’re thrilled to announce that AIM at Melanoma…

By Mara Klecker Page Weinstein has a special request for photographers who take her portraits: Don’t edit out the scar…

Introduction Immunotherapy drugs like ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda), and others are powerful tools to combat melanoma. Indeed, recent…

A Q&A with an Investigator at the National Institutes of Health Dr. Michael Sargen M.D. is an Assistant Clinical Investigator…

This month, we delve into one of the most groundbreaking developments in melanoma research: vaccines. Our spotlight article examines the potential of mRNA…